Free Trial

HC Wainwright Issues Pessimistic Outlook for GPCR Earnings

Structure Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright lowered its FY2026 earnings forecast for Structure Therapeutics to a loss of $2.18 per share from $1.84, while maintaining a Buy rating. It expects the company to remain loss-making through FY2030.
  • Structure Therapeutics reported a quarterly loss of $0.66 per share, missing the consensus estimate of a $0.51 loss by $0.15.
  • Analyst sentiment is broadly positive despite the projected losses: MarketBeat reports a consensus “Moderate Buy” rating and an average price target of $110.91.
  • Five stocks to consider instead of Structure Therapeutics.

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) - Research analysts at HC Wainwright dropped their FY2026 EPS estimates for Structure Therapeutics in a report issued on Thursday, November 12th. HC Wainwright analyst A. Ghosh now forecasts that the company will post earnings of ($2.18) per share for the year, down from their previous estimate of ($1.84). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Structure Therapeutics' current full-year earnings is ($2.10) per share. HC Wainwright also issued estimates for Structure Therapeutics' Q4 2026 earnings at ($0.68) EPS, Q3 2027 earnings at ($0.61) EPS, Q4 2027 earnings at ($0.63) EPS, FY2027 earnings at ($2.40) EPS, FY2028 earnings at ($2.70) EPS, FY2029 earnings at ($2.79) EPS and FY2030 earnings at ($2.54) EPS.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.15).

A number of other brokerages have also recently weighed in on GPCR. Citizens Jmp reissued a "market outperform" rating and set a $110.00 price objective on shares of Structure Therapeutics in a report on Wednesday, September 9th. Canaccord Genuity Group set a $111.00 price target on shares of Structure Therapeutics in a research note on Friday, August 7th. Wall Street Zen lowered shares of Structure Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday, October 3rd. Citigroup reaffirmed a "market outperform" rating on shares of Structure Therapeutics in a research note on Friday, August 7th. Finally, Weiss Ratings raised shares of Structure Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, November 4th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Structure Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $110.91.

Get Our Latest Analysis on GPCR

Structure Therapeutics Stock Performance

GPCR opened at $20.00 on Monday. The stock has a 50-day moving average price of $27.88 and a 200-day moving average price of $46.06. Structure Therapeutics has a 12-month low of $18.70 and a 12-month high of $94.90. The stock has a market capitalization of $1.40 billion, a P/E ratio of -15.50 and a beta of -1.12.

Institutional Investors Weigh In On Structure Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of GPCR. Orbimed Advisors LLC grew its holdings in shares of Structure Therapeutics by 27.0% in the first quarter. Orbimed Advisors LLC now owns 1,475,403 shares of the company's stock worth $71,114,000 after purchasing an additional 313,600 shares during the last quarter. Janus Henderson Group PLC increased its stake in shares of Structure Therapeutics by 5.2% in the first quarter. Janus Henderson Group PLC now owns 5,354,981 shares of the company's stock worth $258,260,000 after buying an additional 264,833 shares during the period. Siren L.L.C. increased its stake in shares of Structure Therapeutics by 23.2% in the first quarter. Siren L.L.C. now owns 1,328,698 shares of the company's stock worth $64,043,000 after buying an additional 250,000 shares during the period. SEB Asset Management AB bought a new stake in Structure Therapeutics during the 1st quarter valued at $11,811,000. Finally, Bank of America Corp DE raised its holdings in Structure Therapeutics by 617.0% during the 1st quarter. Bank of America Corp DE now owns 227,132 shares of the company's stock valued at $10,948,000 after buying an additional 195,454 shares during the last quarter. Institutional investors own 91.78% of the company's stock.

More Structure Therapeutics News

Here's some of the latest news about GPCR:

  • Positive Sentiment: HC Wainwright maintained its Buy rating on GPCR, signaling continued confidence in the company despite expected losses. Analysts Offer Predictions for GPCR Q1 Earnings
  • Negative Sentiment: The analyst lowered its FY2026 EPS estimate to a loss of $2.18 per share from $1.84, and its Q4 2026 estimate to a loss of $0.68 from $0.50. HC Wainwright also forecasts losses through FY2030, suggesting GPCR may continue to require investment before reaching profitability.

Structure Therapeutics Company Profile

(Get Free Report)

Structure Therapeutics is a clinical-stage biopharmaceutical company developing medicines for metabolic and other chronic diseases. Its research approach uses structural biology and computational methods to identify and design small-molecule drug candidates. The company's pipeline includes aleniglipron, an oral small-molecule GLP-1 receptor agonist being developed for obesity and related metabolic conditions. Structure Therapeutics is also advancing other drug candidates targeting biological pathways associated with metabolic disease.

Further Reading

Earnings History and Estimates for Structure Therapeutics (NASDAQ:GPCR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Structure Therapeutics Right Now?

Before you consider Structure Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.

While Structure Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines